BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on ...

The search for a treatment for limb-girdle muscular dystrophy was started by the family of former Bank of America Corp. CEO ...

We recently published 10 Big Names Crushing Wall Street. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the top-performing ...

Analysts estimate that BridgeBio Pharma will report an earnings per share (EPS) of $-0.82. The announcement from BridgeBio ...

Fintel reports that on October 27, 2025, HC Wainwright & Co. maintained coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a ...

BridgeBio said an experimental therapy for a rare form of muscular dystrophy succeeded in a key trial, potentially setting up ...

H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $80 from $70 and keeps a Buy rating on the shares. The firm now includes ...

As we enter entrepreneurship month this November, we’re celebrating the professors and alumni who are fueling job creation ...

BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending ...

Stock indexes in the U.S. rose Monday with the rising 1.86%. Meanwhile, the added 1.23%, and the added 0.71%.

Incyte axed three prospects to focus on “high-value programs,” its CEO said. Elsewhere, MapLight priced an IPO during the ...

Bridgebio Pharma says it will seek U.S. approval of BBP-418 for LGMD2i after Phase 3 trial data showed a range of benefits ...